Published: 2020-11-15

In-Depth Reviews

Original Research

Development and Validation of a Diagnostic 35-Gene Expression Profile Test for Ambiguous or Difficult-to-Diagnose Suspicious Pigmented Skin Lesions

Sarah Estrada, Jeffrey Shackelton, Nathan Cleaver, Natalie Depcik-Smith, Clay Cockerell, Stephen Lencioni, Howard Martin, Jeffrey Wilkinson, Lauren Meldi Sholl, Michael Berg, Brooke Russell, Olga Zolochevska, Kyle Covington, Aaron Farberg, Matthew Goldberg, Pedram Gerami, Gregory Hosler
| DOI https://doi.org/10.25251/skin.4.6.3

Page 506-522

A 35-Gene Expression Profile Test for use in Suspicious Pigmented Lesions Impacts Clinical Management Decisions of Dermatopathologists and Dermatologists

Aaron Farberg, Kelli Ahmed, Christine Bailey, Brooke Russell, Kelly Douglas, Clare Johnson, Olga Zolochevska, Robert Cook, Matthew Goldberg
| DOI https://doi.org/10.25251/skin.4.6.4

Page 523-533

An Update on the Global Burden and Socioeconomics of Scabies

Katelyn Urban, Rachel Lynn Giesey, Maria Delost, Gregory Raymond Delost
| DOI https://doi.org/10.25251/skin.4.6.5

Page 534-542

Research Letters

755-nm Alexandrite Laser for the Treatment of Non-Facial Superficial and Nodular Basal Cell Carcinoma

Valerie Shiu, Margaret Brown, Pavela Bambekova, Jenny Yeh, Jaqueline Brogan, Catherine Kowalewski
| DOI https://doi.org/10.25251/skin.4.6.7

Page 548-551

Brief Articles

Merkel Cell Carcinoma Presenting as an Indurated Plaque

Margaret Coleman Maxi, Joel Byrne, Ardenne Martin, Pamela Martin
| DOI https://doi.org/10.25251/skin.4.6.10

Page 559-562

Palmoplantar Pityriasis Rosea

Aurel Apple, Ann Lin, Angela Kim, Suzanne Rozenberg, Rachel Kushner
| DOI https://doi.org/10.25251/skin.4.6.13

Page 571-574

Cutaneous Toxicities of PI3K Inhibitors: A Series of Two Cases and Review of the Literature

Simran Arinder Chadha, Jennifer Shastry, Joel Sunshine, Jennifer Choi, Lauren Guggina
| DOI https://doi.org/10.25251/skin.4.6.16

Page 585-590

Painful Retiform Purpura with Cutaneous Necrosis

Alfredo Siller Jr., Joseph Jebain, Yomna Amer, Christopher T. Haley, Leon Chen, Stephen K. Tyring
| DOI https://doi.org/10.25251/skin.4.6.18

Page 595-598

Ixekizumab Overdose: A Case Report

Margaret L. Snyder, MD, Mark G. Lebwohl, MD
| DOI https://doi.org/10.25251/skin.4.6.20

Page 603-607

A Rapidly Enlarging Solitary Infantile Myofibroma

Stephany Vittitow, Merrick Kozak, Reza Daughtery, Barrett Zlotoff
| DOI https://doi.org/10.25251/skin.4.6.21

Page 608-612

Elephantiasis Nostras Verrucosa

Graham H Litchman, Lauren Schwartzberg, Suzanne Friedler, Suzanne Sirota Rozenberg
| DOI https://doi.org/10.25251/skin.4.6.22

Page 613-616

Short Communications

Eccrine Porocarcinoma Masquerading as Squamous Cell Carcinoma

Drew Kuraitis, Yong Lee, Abida Kadi, Andrea Murina
| DOI https://doi.org/10.25251/skin.4.6.24

Page 620-622

Compelling Comments

Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis

Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

Leon Kircik, Mark Lebwohl, Kim Papp, Melinda Gooderham, Linda Stein Gold, Zoe Draelos, Steven Kempers, Stephen Tyring, Lorne Albrecht, Marni Wiseman, Laura Ferris, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk
| DOI https://doi.org/10.25251/skin.4.supp.70

Page s70

Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

Linda Stein Gold, Mark Lebwohl, Kim Papp, Melinda Gooderham, Leon Kircik, Zoe Draelos, Steven Kempers, David Pariser, Javier Alonso-Llamazares, Darryl Toth, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk
| DOI https://doi.org/10.25251/skin.4.supp.71

Page s71

Maximal Use Study of Tapinarof Cream 1% in Subjects with Extensive Plaque Psoriasis

John Jett, Michael McLaughlin, Mark Lee, Lawrence Parish, Glenn Tabolt, Timothy Wilson, Matthew Somerville, Wayne DellaMaestra, Stephen Piscitelli
| DOI https://doi.org/10.25251/skin.4.supp.74

Page s74

Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials

Mark Lebwohl, Linda Stein Gold, Bruce Strober, April Armstrong, H Chih-Ho Hong, Leon Kircik, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen Piscitelli, David Rubenstein, Philip Brown, Anna Tallman, Robert Bissonnette
| DOI https://doi.org/10.25251/skin.4.supp.75

Page s75

Acne & Rosacea

Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race

Fran E Cook-Bolden, Neal Bhatia, Jonathan S Weiss, Neil Sadick, Stephen K Tyring, Eric Guenin, Anya Loncaric, Susan Harris
| DOI https://doi.org/10.25251/skin.4.supp.88

Page s88

Atopic Dermatitis

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study

Melinda J. Gooderham, Leon H. Kircik, Matthew Zirwas, Mark Lee, Steven E. Kempers, Zoe D. Draelos, Laura Ferris, Terry M. Jones, Etienne Saint-Cyr Proulx, Robert Bissonnette, Neal Bhatia, Scott T. Guenthner, Robert A. Koppel, Howard Welgus, Charlotte Merritt, Meg Elias, Lynn Navale, Robert C. Higham, Michael Droege, David R. Berk
| DOI https://doi.org/10.25251/skin.4.supp.93

Page s93

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Michael E. Kuligowski, May E. Venturanza, Kang Sun, Eric L. Simpson
| DOI https://doi.org/10.25251/skin.4.supp.95

Page s95

Efficacy and Safety of Tralokinumab with Concomitant Topical Corticosteroids in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of the ECZTRA 3 Trial

Boni E. Elewski, Matthew J. Zirwas, Richard G. Langley, Andrew F. Alexis, Karen A. Veverka, John Zoidis, Azra Kurbasic, Jonathan I. Silverberg
| DOI https://doi.org/10.25251/skin.4.supp.97

Page s97

Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Jonathan I. Silverberg, Michael Cork, Andreas Wollenberg, Norito Katoh, Louise Abildgaard Steffensen, Azra Kurbasic, Christina Kurre Olsen, Alexandra Kuznetsova, Marie Louise Østerdal, Andreas Westh Vilsbøll, Mette Deleuran
| DOI https://doi.org/10.25251/skin.4.supp.98

Page s98

Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis

Michael Cork, Diamant Thaçi, Lawrence Eichenfield, Peter Arkwright, Zhen Chen, Mohamed Kamal, John O'Malley, Ashish Bansal
| DOI https://doi.org/10.25251/skin.4.supp.104

Page s104

Dermatopharmacology

Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors

Anjaneya Chimalakonda, James Burke, Lihong Cheng, Ian Catlett, Aditya Patel, Jun Shen, Ihab Girgis, Subhashis Banerjee, John Throup
| DOI https://doi.org/10.25251/skin.4.supp.108

Page s108

Review of Mechanisms of Release of Commonly Prescribed Tetracyclines

Pearl Kwong, Hilary Baldwin, Debbie Glaab, Rhonda Schreiber, Emma Hignett
| DOI https://doi.org/10.25251/skin.4.supp.110

Page s110

Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

Caroline Robert, Jean Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Paul Nathan, Antoni Ribas, Michael Davies, Keith Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Dirk Schadendorf, Georgina Long
| DOI https://doi.org/10.25251/skin.4.supp.112

Page s112

Hyperhidrosis

Skin Cancer

Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies

Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler, Mark Lebwohl
| DOI https://doi.org/10.25251/skin.4.supp.120

Page s120

Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies

Andrew Blauvelt, Steven Kempers, Todd Schlesinger, Edward Lain, Hui Wang, David Cutler, Mark Lebwohl, Jane Fang, Rudolf Kwan
| DOI https://doi.org/10.25251/skin.4.supp.121

Page s121

Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Michael Migden, Danny Rischin, Medha Sasane, Vera Mastey, Anna Pavlick, Chrysalyne Schmults, Zhen Chen, Alexander Guminski, Axel Hauschild, Denise Bury, Anne Lynn Chang, Guilherme Rabinowits, Sheriff Ibrahim, Israel Lowy, Matthew Fury, Siyu Li, Chieh-I Chen
| DOI https://doi.org/10.25251/skin.4.supp.122

Page s122

Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

Danny Rischin, Nikhil Khushalani, Chryslalyne Schmults, Alexander Guminski, Anne Lynn Chang, Karl Lewis, Annette Lim, Leonel Hernandez-Aya, Brett Hughes, Dirk Schadendorf, Axel Hauschild, Elizabeth Stankevich, Jocelyn Booth, Suk-Young Yoo, Zhen Chen, Emmanuel Okoye, Israel Lowy, Matthew Fury, Micahel Migden
| DOI https://doi.org/10.25251/skin.4.supp.124

Page s124

Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Guilherme Rabinowits, Jade Homsi, Mina Nikanjam, Rhonda Gentry, John Strasswimmer, Suraj Venna, Michael Migden, Sunandana Chandra, Emily Ruiz, Haixin Zhang, Jennifer McGinniss, Alex Seluzhytsky, Jigar Desai
| DOI https://doi.org/10.25251/skin.4.supp.125

Page s125

Combining DNA and RNA Analyses Enhances Non-Invasive Early Detection of Cutaneous Melanoma

Stepnaie Cullison, Laura Ferris, Zuxu Yao, Claudia Ibarra, Michael Howell, Burkhard Jansen
| DOI https://doi.org/10.25251/skin.4.supp.126

Page s126

Miscellaneous